In the difficult-to-treat subgroup of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid aspirin-exacerbated respiratory disease, dupilumab significantly improved CRSwNP disease outcomes, along with asthma control and lung function. This is preliminary evidence of the effect of dupilumab in patients with CRSwNP and comorbid aspirin- exacerbated respiratory disease
Jean Kim,1,2 Robert Naclerio1 1Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Uni...
BACKGROUND: Type 2 inflammatory diseases often coexist in patients. Dupilumab targets type 2 inflamm...
Background Chronic rhinosinusitis with nasal polyposis (CRSwNP) is associated with substantial sinus...
In the difficult-to-treat subgroup of patients with chronic rhinosinusitis with nasal polyps (CRSwNP...
BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) affects 7% of asthmatics. Usual therapies...
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) and type 2 asthma share the same infla...
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common inflammatory condition affecting the u...
Background About one-tenth of patients with difficult-to-treat chronic rhinosinusitis with nasal pol...
IMPORTANCE: Dupilumab has demonstrated efficacy in patients with asthma and atopic dermatitis, which...
Background: Biologics are currently one of the main treatment options for a number of diseases. The ...
BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for I...
Background: Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally have a high sy...
Background: Comorbid perennial allergic rhinitis (PAR) or year-round aeroallergen sensitivity substa...
Dupilumab has been shown to be safe and effective in treating chronic rhinosinusitis with polyposis ...
Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2-mediated infl...
Jean Kim,1,2 Robert Naclerio1 1Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Uni...
BACKGROUND: Type 2 inflammatory diseases often coexist in patients. Dupilumab targets type 2 inflamm...
Background Chronic rhinosinusitis with nasal polyposis (CRSwNP) is associated with substantial sinus...
In the difficult-to-treat subgroup of patients with chronic rhinosinusitis with nasal polyps (CRSwNP...
BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) affects 7% of asthmatics. Usual therapies...
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) and type 2 asthma share the same infla...
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a common inflammatory condition affecting the u...
Background About one-tenth of patients with difficult-to-treat chronic rhinosinusitis with nasal pol...
IMPORTANCE: Dupilumab has demonstrated efficacy in patients with asthma and atopic dermatitis, which...
Background: Biologics are currently one of the main treatment options for a number of diseases. The ...
BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for I...
Background: Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally have a high sy...
Background: Comorbid perennial allergic rhinitis (PAR) or year-round aeroallergen sensitivity substa...
Dupilumab has been shown to be safe and effective in treating chronic rhinosinusitis with polyposis ...
Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2-mediated infl...
Jean Kim,1,2 Robert Naclerio1 1Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Uni...
BACKGROUND: Type 2 inflammatory diseases often coexist in patients. Dupilumab targets type 2 inflamm...
Background Chronic rhinosinusitis with nasal polyposis (CRSwNP) is associated with substantial sinus...